The accumulation of data over the last 30 years that TGFβ1 plays several key roles in the progression of cancer and increasing evidence from animal and preclinical studies demonstrating the anti-tumor efficacy of many strategies that interfere with TGFβ1 activity have together made TGFβ1 an attractive target for cancer therapy in patients. The gene discussed is TGFB1; the disease is cancer.